In 2022, more than 40% of countries experienced malaria outbreaks, resulting in approximately 249 million infections. Although malaria is preventable and curable, the most severe cases occur in regions with fragile health care systems, primarily in the developing world’s poorest countries. Malaria treatment is crucial in these areas, where the disease is both a cause and effect of poverty.

Malaria’s Impact and Transmission

Malaria, a deadly parasite, spreads through specific mosquito species and not directly from person to person, except through contaminated needles or blood transfusions. This disease can cause severe illness and death within just 24 hours of infection. In 2020, malaria claimed more lives in Africa than COVID-19, with four countries alone contributing to 50% of the global malaria death toll. Tragically, in Africa, 80% of malaria fatalities among children occur before their fifth birthday. An estimated 40 million children in the region could benefit from a malaria vaccine.

Celebrity Advocacy: David Beckham’s Role

David Beckham, an iconic English football star, achieved fame playing under Sir Alex Ferguson at Manchester United, where he contributed to winning six Premier League titles. Since retiring, Beckham has leveraged his status to advocate for various causes. As a UNICEF Goodwill Ambassador since 2005, he supports the #TogetherBand Campaign and has long championed the fight against malaria. He has backed Malaria No More UK since 2009 and was the face of the world’s first voice petition to end malaria with MalariaMustDie in 2019.

Advances in Malaria Treatment

Scientists have actively pursued new malaria treatments and vaccines since the 1980s, achieving notable success with the RTS,S/AS01 (RTS,S) vaccine. Since 2019, this new treatment has been administered in Ghana, Kenya and Malawi, reaching more than two million people and reducing early childhood deaths from all causes by 13%. The vaccine primarily benefits children who lack other forms of malaria protection. An expanded rollout to 18 additional countries has been approved, although vaccine supplies remain limited.

In 2023, the successful introduction of the first malaria vaccine was followed by the launch of the R21/Matrix-M vaccine, which boasts a 75% efficacy rate, meeting a World Health Organization (WHO) target that the 2019 vaccine did not meet. Adrian Hill, the chief investigator for the R21/Matrix-M malaria vaccine, asserts that it represents the most effective single intervention against malaria due to its scalability and affordability, costing only $3.90 per dose.

Future Directions and Global Impact

Organizations such as Gavi, the Vaccine Alliance, are actively developing strategies to distribute this lifesaving vaccine. Their roadmap projects a need for up to 60 million doses by 2026 and 100 million doses annually by 2030. Their mission focuses on promoting the equitable and sustainable use of vaccines. They collaborate with major partners including the WHO, UNICEF, the World Bank and the Bill and Melinda Gates Foundation to save lives globally.

Looking Forward: Progress in Malaria Treatment

This new malaria treatment is crucial as previous methods have shown limitations. Mosquitoes carrying malaria have developed resistance to insecticides used to control their population and the parasite itself is increasingly resistant to current oral malaria drugs. In an interview with Nadine Dreyer and HealthWorld, Adrian Hill states that the fight against malaria is gaining momentum and he is aware of other vaccines in development. With ongoing innovations in vaccinations and the expansion of global distribution for existing treatments, there is a greater chance of achieving the Sustainable Development Goals by 2030, which the escalating threat from malaria could otherwise hinder.

– Rachael Denton-Snape

Rachael is based in High Wycombe, UK and focuses on Technology and Global Health for The Borgen Project.

Photo: Flickr